Our unique ability to reproduce the pathological targets and processes implicated in Neurodegenerative Diseases (NDs) has allowed ND Biosciences to develop an integrated pre-clinical drug discovery program with unprecedented translational potential. We have strategically centered our drug discovery pipeline on the development of therapeutics that capture the biochemical and structural diversity of pathology in NDs, and that can thus interfere with processes related to different stages of disease pathology.
Currently, we have three therapeutic programs focused on Parkinson’s disease that are at early discovery and POC phase. These programs are centered on the inhibition of α-Syn spreading and seeding, the promotion of clearance of pathologic α-Syn species, and native-state stabilization of physiological α-Syn proteoforms. As we proceed with this first set of programs, ND Biosciences will continue to utilize its proprietary R&D discovery platforms to identify and validate new targets and therapeutic molecules, thereby developing additional programs, and expanding into more indications.